PNC Financial Services Group
RNAC icon

PNC Financial Services Group’s Cartesian Therapeutics RNAC Stock Holding History

PNC Financial Services Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221 Buy
36
+31
+620% +$221 ﹤0.01% 5022
2025
Q4 		$36 Buy
+5
New +$40 ﹤0.01% 5113
2022
Q3 		– Sell
-2
Closed – – 4587
2022
Q2 		$0 Buy
+2
New +$59 ﹤0.01% 4679

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PNC Financial Services Group's RNAC Position: Q1 2026 in Review

PNC Financial Services Group increased its Cartesian Therapeutics (RNAC) stake by 620% in Q1 2026, buying an estimated $221 and bringing the position to 36 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #5022.

PNC Financial Services Group first reported a position in RNAC in Q2 2022 and has held it in 3 quarters since. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • PNC Financial Services Group held 36 shares of Cartesian Therapeutics worth $221 as of Q1 2026.
  • PNC Financial Services Group bought 31 Cartesian Therapeutics shares in Q1 2026, an estimated $221.
  • Cartesian Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5022 holding.
  • PNC Financial Services Group first reported a position in Cartesian Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.